全聘课题组长
首页  人才队伍  全聘课题组长
  • 柳素玲

    博士,教授,硕士和博士生导师
    地址:东安路270号,复旦大学附属肿瘤医院2号楼1317B室,上海 200032
    电话:021-34771023(办公室),021-34774409 (实验室)
    邮箱:suling@fudan.edu.cn

工作经历
教授,复旦大学,生物医学研究院/附属肿瘤医院(2016.12-今)
教授,中国科学技术大学,生命科学学院(2012.11-2016.11)
研究助理教授,美国密西根大学(2010.10-2012.10)
助理研究员,美国密西根大学(2006.10-2010.09)
博士后,美国密西根大学(2003.12-2006.09)
教育经历
博士,美国俄亥俄州立大学,生物学系(1997-2003)
学士,中国科学技术大学,生物系(1992-1997)
所获人才项目

上海市领军人才,上海市委和上海人社局,2021
科技部中青年科技创新领军人才,科技部,2020
上海市科技创新行动计划学术带头人,2020
复旦大学“卓越2025”:卓识杰出人才, 复旦大学,2020
上海市医学领军人才,上海市卫健委,2019
国家优秀青年科学基金,国家自然科学基金委,2014
海外高层次人才引进计划青年项目,中组部,2012

所获奖项

药明康德生命化学研究奖,2020
中国肿瘤青年科学家奖,中国抗癌协会,2018
中美抗癌协会-美国国家癌症基金学术奖,中美抗癌协会,2014
Susan G. Komen Scholar in Training Award,美国癌症协会,2010
Merck Scholar in Training Award,美国癌症协会,2006

研究方向
1)乳腺肿瘤干细胞的异质性及其调控和耐药研究;
2)乳腺肿瘤干细胞的起源研究;
3)肿瘤微环境与肿瘤干细胞的互作研究;
4)肿瘤干细胞的免疫调控研究;
5)靶向肿瘤干细胞的新型治疗策略研究及药物开发。
招生专业
生物化学与分子生物学
代表论文(近五年)

1.Sheng, D., Ma, W., Zhang, R., Zhou, L., Deng, Q., Tu, J., Chen, W., Zhang, F., Gao, N., Dong, M., Wang, D., Li, F., Liu, Y., He, X., Duan, S., Zhang, L., Liu, T.*, Liu, S.*. Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization. Journal for ImmunoTherapy of Cancer (online), 2022.

2.Zhang, R.#, Tu, J.#, Liu, S.*. Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity. Seminars in Cancer Biology 82:11-25, 2022. PMID: 33737107

3.Xu, J., Yang, X., Deng, Q., Yang, C., Wang, D., Jiang, G., Yao, X., He, X., Ding, J., Qiang, J., Tu, J., Zhang, R., Lei, Q., Shao, Z-M., Bian, X.*, Hu, R.*, Zhang, L.*, Liu, S.*. TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer. Nature Communications 12: 4413, 2021. PMID: 34285210

4.Liu, C., Qiang, J., Deng, Q., Xia, J., Deng, L., Zhou, L., Wang, D., He, X., Liu, Y., Zhao, B., Lv, J., Yu, Z., Lei, Q., Shao, Z.*, Zhang, X.*, Zhang, L.*, Liu, S.*  ALDH1A1 activity in tumor -initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression. Cancer Research 81(23):5919-5934, 2021. PMID: 34580061

5.Jiang, G.#, Tu, J.#, Zhou, L.#, Dong, M., Fan, J., Chang, Z., Zhang, L., Bian, X., Liu, S.* Single-cell transcriptomics reveal the heterogeneity and dynamic of cancer stem-like cells during breast tumor progression. Cell Death and Disease 12(11):979, 2021. 

6.Li, F. #, Xu, J. #, Liu, S.*  Cancer Stem Cells and Neovascularization. Cells 10 (5):1070, 2021.

7.Huang, Y.#, Wang, H., Hao, Y., Lin, H., Dong, M., Ye, J., Song, L., Wang, Y., Li, Q., Shan, B., Jiang, Y., Li, H., Shao, Z.M., Kroemer, G., Zhang, H., Bai, L., Jin, T., Wang, C., Ma, Y., Cai, Y., Ding, C., Liu, S.*,Pan, Y.*, Jiang, W.*, Zhou R.*. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. Nature Cell Biology 22(6):716-727, 2020.PMID:32367047

8.Zhang, F. #, Liu, B., Deng, Q., Sheng, D., Xu, J., He, X., Zhang, L.*, Liu, S.*. UCP1 regulates ALDH-positive breast cancer stem cells through releasing the suppression of Snail on FBP1. Cell Biol Toxicol (online), 2020. PMID:32472219

9.Zhang, F. #, Liu, S.*. Mechanistic insights of adipocyte metabolism in regulating breast cancer progression. Pharmacological Research 6(155):104741, 2020. PMID:32151679

10.Qin, Y. #, Chen, W. #, Jiang, G., Zhou, L., Yang, X., Li, H., He, X., Wang, H., Zhou, Y., Huang, S., Liu, S.*. Interfering MSN-NONO complex activated CREB signaling serves a novel therapeutic strategy for triple-negative breast cancer, Science Advances 6(8), 2020.PMID:32128390.

11.Zhang, L. #, Qiang, J. #, Yang, L. #, Wang, D., Adeel, R., He, X., Chen, W., Sheng , D., Zhou, L., Jiang, Y. Z., Li, T., Du, Y., Feng, J., Hu, X., Zhang, J., Hu, X. C., Shao, Z. M., Liu, S.*. IL1R2 blockade suppresses breast tumorigenesis and progression by impairing USP15-dependent BMI1 stability. Advanced Science 7(1):1901728, 2020. PMID: 31921558

12.Zhou L. #, Wang, D. #, Sheng, D. #, Xu, J., Chen, W., Qin, Y., Du, R., Yang, X., He, X., Xie, N.*, Liu, S.*, Zhang, L.*. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer. Theranostics 10(5): 2405-2421, 2020.PMID:32104513.

13.Zhang, J., Yang, Y., Zhou, S., He, X., Cao, X., Wu, C., Hu, H., Qin, J., Wei, G., Wang, H., Liu, S.*, Sun, L.*. Membrane-bound TNF mediates microtubule-targeting chemotherapeutics-induced cancer cytolysis via juxtacrine inter-cancer-cell death signaling. Cell Death and Differentiation 485, 2019. PMID: 31645676

14.Jiang, G.#, Wang, X.#, Sheng, D., Zhou, L., Liu, Y., Xu, C., Liu, S.* and Zhang, J.*. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function. Theranostics 9(22): 6501-6516, 2019. PMID: 31588232

15.Jin, X. #, Xu, X-E. # *, Jiang, Y-Z. #, Liu, Y-R., Sun, W., Guo, Y-J., Ren, Y-X., Zuo, W-J., Hu, X., Huang, S-L., Shen, H-J., Lan, F., He, Y-F., Hu, G-H., Di, G-H., He, X-H., Li, D-Q., Liu, S.*, Yu, K-D.*,, Shao, Z-M.*. The endogenous retrovirus-derived long noncodingRNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. Science Advances 5(3): eaat9820, 2019. PMID: 30854423

16.Cui, B., Luo, Y., Tian, P., Peng, F., Lu, J., Yang, Y., Su, Q., Liu, B., Yu, J., Luo, X., Yin, L., Cheng, W., An, F., He, B., Liang, D., Wu, S., Chu, P., Song, L., Liu, X., Luo, H., Xu, J., Pan, Y., Wang, Y., Li, D., Huang, P., Yang, Q., Zhang, L., Zhou, B.P., Liu, S., Xu, G.,Lam, E.W.-F., Kelley, K.W. and Liu, Q.*. Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells. JCI 129(3):1030-1046, 2019. PMID: 30688660

17.Liu, J., Duan, Z., Guo, W., Zeng, L., Wu, Y., Chen, Y., Tai, F., Wang, Y., Lin, Y., Zhang, Q., He, Y., Deng J., Stewart, R., Wang, C., Lin, P., Ghaffari, S., Evers, B.M., Liu, S.*, Zhou, M-M.*, Zhou, B.*, and Shi, J.*. Targeting the BRD4/FOXO3a/CDK6 axis Sensitizes AKT Inhibition in Luminal Breast Cancer. Nature Communications 9(1):5200, 2018. PMID: 30518851

18.Liu, B., Du, R., Zhou L., Xu, J., Chen, S., Chen, J., Yang, X., Liu, D-X., Shao, Z-M., Zhang, L., Yu, Z., Xie, N. *, Guan, J-L.*, and Liu, S.*. miR-200c/141 regulates breast cancer stem cell heterogeneity via targeting HIPK1/β-catenin axis. Theranostics 8(21):5801-5813, 2018. PMID: 30613263

19.Deng, L., Gao, X., Liu, B., He, X., Xu, J., Qiang, J., Wu, Q., Liu, S.*. NMT1 inhibition modulates breast cancer progression through stress-triggered JNK pathway. Cell Death and Disease 9(12):1143, 2018. PMID: 30446635

20.Chen, L-L., Lin, H-P., Zhou, W-J., He, C-X., Zhang, Z-Y., Cheng, Z-L., Song, J-B., Liu, P., Chen, X-Y., Xia, Y-K., Chen, X-F., Sun, R-Q., Zhang, J-Y., Sun, Y-P., Song, L., Liu, B-J., Du, R-K., Ding, C., Lan, F., Huang, S-L., Zhou, F., Liu, S., Xiong, Y.*, Ye, D.*, Guan, K-L.*SNIP1 recruits TET2 to regulate c-MYC target genes and cellular DNA damage response. Cell Reports 25(6):1485-1500, 2018. PMID: 30404004

21.Chen, W., Qin, Y., Wang, D., Zhou, L., Liu, Y., Chen, S., Yin, L., Xiao, Y., Yao, X-H., Yang, X., Ma, W., Chen, W., He, X., Zhang, L., Yang, Q., Bian, X., Shao, Z-M., Liu, S.*CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. Plos Biology 16(7):e2005869, 2018. PMID: 30052635

22.Chen, F., Long, Q., Fu, D., Zhu, D., Ji, Y., Han, L., Zhang, B., Xu, Q., Liu, B., Li, Y., Wu, S., Yang, C., Qian, M., Xu, J., Liu, S., Cao, L., Chin, E.Y., Lam, E.W.F., Coppé, J-P., Sun, Y. Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. Nature Communications 9:4315, 2018.

23.Liu, M., Liu, Y., Deng, L., Wang, D., He, X., Zhou, L., Wicha, M.S., Bai, F.*, Liu, S.*.Transcriptionalprofiles of differentstates of cancerstem cells in triple-negative breast cancer.Mol Cancer 17(1):65, 2018. PMID: 29471829

24.Du, R., Liu, B., Zhou, L., Wang, D., He, X., Xu, X., Zhang, L., Niu, C.*, Liu, S.*. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer.Cell Death and Disease 9(2):126, 2018. PMID: 29374148

25.Wang, D., Xu, J., Liu, B., He, X., Zhou, L., Hu, X., Qiao, F., Zhang, A., Xu, X., Zhang, H., Wicha, MS., Zhang, L., Shao, Z., Liu, S.*. IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer. Cell Death and Differentiation 25(2):330-339, 2018. PMID: 29027990

26.Zhou, L., Sheng, D., Deng, Q., Wang, D., Liu, S.*. Development of a novel method for rapid cloning of shRNA vectors, which successfully knocked down CD44 in mesenchymal-like triple negative breast cancer cells. Cancer Communications 38(1):57, 2018. PMID: 30249304

27.Zhou, L., Sheng, D., Wang, D., Ma, W., Deng, Q., Deng, L., Liu, S.*. Identification of cancer-type specific expression patterns for active aldehyde dehydrogenase (ALDH) isoforms in ALDEFLUOR assay. Cell Biol Toxicol (online) 2018. PMID: 30220009

28.Chen, W., Qin, Y., Liu, S.*. Cytokines, breast cancer stem cells(BCSCs) and chemoresistance. Clinical and Translational Medicine 7(27), 2018.

29.Qin, Y., Chen, W., Liu, B., Zhou, L., Deng, L., Niu, W., Bao, D., Cheng, C., Li, D., Liu, S.*, Niu, C.*. MiR-200c Inhibits the Tumor Progression of Glioma via Targeting Moesin. Theranostics 7(6):1663-1673, 2017.

30.Zhang, Y.Y. Li,C., Yao, G.F., Du, L.J., Liu, Y., Zheng, X.J., Yan, S., Sun, J.Y., Liu, Y., Liu, M.Z., Zhang, X., Wei, G., Tong, W., Chen, X., Wu, Y., Sun, S., Liu, S., Ding, Q., Yu, Y., Yin, H., Duan, S.Z.. Deletion of Macrophage Mineralocorticoid Receptor Protects Hepatic Steatosis and Insulin Resistance Through ERα/HGF/Met Pathway. Diabetes 66(6):1535-1547, 2017. PMID: 28325853

31.Wang, D., Du, R., Liu, S.* Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer. Chin J Cancer 36(1):37, 2017 PMID: 28359295

32.Liu, Y., Burness, M.L.*, Martin-Trevino, R., Guy, J., Bai, S., Harouaka, R., Brooks, M.D., Shang, L., Fox, A., Luther, T.K., Davis, A., Baker, T.L., Colacino, J., Clouthier, S.G., Shao, Z-M., Wicha, M.S., and Liu, S*. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer. Clinical Cancer Research , 2017.



Top